Current technologies for visualizing infectious pathways of viruses rely on fluorescent labeling of capsid proteins by chemical conjugation or genetic manipulation. For noninvasive in vivo imaging of such agents in mammalian tissue, we engineered bioluminescent Gaussia luciferase-tagged Adeno-associated viral (gLuc/AAV) vectors. The enzyme was incorporated into recombinant AAV serotypes 1, 2 and 8 capsids by fusing to the N-terminus of the VP2 capsid subunit to yield bioluminescent virion shells. The gLuc/AAV vectors were used to quantify kinetics of cell-surface-binding by AAV2 capsids in vitro. Bioluminescent virion shells displayed an exponential decrease in luminescent signal following cellular uptake in vitro. A similar trend was observed following intramuscular injection in vivo, although the rate of decline in bioluminescent signal varied markedly between AAV serotypes. gLuc/AAV1 and gLuc/AAV8 vectors displayed rapid decrease in bioluminescent signal to background levels within 30 min, whereas the signal from gLuc/ AAV2 vectors persisted for over 2 h. Bioluminescent virion shells might be particularly useful in quantifying dynamics of viral vector uptake in cells and peripheral tissues in live animals.
Adeno-associated viral (AAV) vectors have recently gained popularity in gene transfer applications owing to the availability of a vector tool kit comprised of several serotypes and variants exhibiting diverse tissue tropisms. 1 Tracking the in vivo biodistribution and tissue tropisms of AAV vectors is critical toward understanding their infectious pathways and establishing safety for human gene transfer applications. Fusion constructs of viral capsid subunits and fluorescent proteins, such as green fluorescent protein (GFP), have had tremendous impact as reagents for elucidating infectious pathways of viruses in vitro through confocal microscopy techniques. 2, 3 However, such fluorescence-based imaging techniques for tracking viral vectors in live animals might not be feasible in light of the low vector concentrations (doses ranging from 10 9 to 10 12 particles; pico-femtomolar range), high background autofluorescence and the resultant weak signal-to-background ratio in vivo. 4, 5 Radioisotope-based imaging techniques are perhaps ideally suited for such in vivo studies, 6 although significant challenges pertaining to radiochemical labeling of viruses and subsequent access to radio-imaging technology remain to be addressed.
The current, most widely used modality for understanding viral vector tropism in vivo is to monitor expression levels/patterns of a luciferase reporter gene incorporated into the vector genome using live animal bioluminescence imaging. 7 The latter approach, although somewhat informative of vector tissue tropisms, cannot be used to accurately predict dynamics of vector dissemination from or vector uptake at the site of administration. To address these issues, we have developed a simple strategy that involves a viral capsidluciferase fusion protein, which when incorporated into the AAV capsid during production results in the generation of bioluminescent AAV shells that can be monitored using live animal imaging.
The AAV capsid is comprised of three viral protein subunits, Vp1, Vp2 and Vp3.
8 Vp1 and Vp3 are critical for forming infectious virions, whereas Vp2 is thought to be redundant. Further, the N-terminus of Vp2 can tolerate fusion with large proteins, such as GFP (B30 kDa), thereby allowing incorporation and surface display of nonendogenous viral proteins on the AAV capsid. 2 Using the latter strategy, we engineered Gaussia luciferase (gLuc; 19 kDa), a highly sensitive luciferase, 9, 10 to the N-terminus of the Vp2 protein derived from the AAV2 capsid sequence. Briefly, the gLuc transgene was amplified from the plasmid pGLuc (Nanolight, Pinetop, AZ, USA) by PCR, using primers (AGTACTATATA; GATATAGATAGAG) flanked by EagI and MluI sites, and the PCR product was ligated to pVp2AGFP, following restriction digestion, to generate pVp2AgLuc. Bioluminescent gLuc/AAV1, gLuc/AAV2 and gLuc/AAV8 capsids packaging the GFP transgene driven by the CMV promoter were generated as per the schematic shown in Figure 1 . The pXR-ACA and pVp2AGFP plasmids, in which the Vp2 start site is mutated from ACG to ACA and ATG, respectively, have been described previously.
11,2 Vector genome-containing particles were purified by cesium chloride density ultracentrifugation, dialyzed against phosphate-buffered saline (PBS) and viral titers determined using dot blot as described earlier. 12 Genomic titers of gLuc/AAV vectors displayed an inverse correlation to the ratio between plasmids pVp2AgLuc and pXR-ACA used in transfection, with ratios of 25:75 or lower yielding genomic titers comparable to that of recombinant AAV vectors (B10 12 vector genome-containing particles per ml). These results are in agreement with those described by Warrington et al. 2 for AAV capsids containing similar Vp2-GFP fusion proteins.
Bioluminescence of (10 9 ) viral particles was determined using 50 ml of coelenterazine substrate (CLZ, 40 mg ml À1 ) in 0.1 M Tris buffer (pH 7.5) containing 0.6 M NaCl with a Victor2 bioluminescence plate reader (Perkin Elmer, Waltham, MA, USA). As shown in Figure  2 , transfection of a 10:90 ratio of plasmids pVp2gLuc/ pXR-ACA afforded gLuc/AAV2 capsids with a high bioluminescent signal (a) without adversely affecting transduction efficiency (b) or viral titer (data not shown). Two different viral vector preparations were assessed for their ability to emit bioluminescent signal. Transduction experiments were carried out with HEK293 cells using a multiplicity of infection of 1000, and GFP transgene expression was monitored 24 h post-transduction using fluorescence microscopy. Higher levels of incorporation of the gLuc-Vp2 fusion construct into AAV capsids (plasmid ratio 25:75 or higher) resulted in decreased viral titer or low transduction efficiency (data not shown). On the basis of these results, gLuc/AAV vectors used for all further analysis were generated using a pVp2AgLuc-topXRACA plasmid ratio of 10:90, previously established to minimally impact titer and transduction efficiency.
The gLuc/AAV capsids were first evaluated as potential reagents for quantifying cell-surface-binding and uptake events. Briefly, HeLaS3 cells maintained in suspension culture as per ATCC recommendations were incubated at 4 1C for different time intervals with (a) gLuc/AAV2 capsids and (b) gLuc/AAV2 capsids preincubated with heparin for 1 h on ice (30 mg ml
À1
; Sigma, St Louis, MD, USA) at a multiplicity of infection of 10 000. For binding studies, 10 6 cells were spun down, the cell pellet washed thrice with cold 1 Â PBS and luminometric assays with CLZ substrate (40 mg ml À1 ) carried out as described earlier. As shown in Figure 3a , gLuc/AAV2 capsids display saturable binding to the surface of HeLaS3 cells. 13 Pre-incubation with heparin reduced the number of cell-surface-bound viral particles by four-to fivefold, corroborating the use of heparan sulfate by gLuc/AAV2 as the primary receptor. 14 The total number of cell-surface-bound viral particles was determined to be B700 per HeLaS3 cell, and peak binding levels were achieved 2 h post-incubation at 4 1C. The number of cell-surface-bound gLuc/AAV2 capsids was determined by fitting the total signal from gLuc/ AAV2 capsids bound to HeLaS3 cells at 2 h postincubation (following the final PBS wash step) in a standard curve correlating luminescent signal with serial dilutions of gLuc/AAV2 capsids.
For cellular uptake studies, HeLaS3 cells were incubated with gLuc/AAV2 capsids for 2 h at 4 1C, pelleted, washed three times with DMEM containing 10% FBS and incubated at 37 1C to allow internalization. Cells (10 7 ) were removed at different time points, lysed using passive lysis buffer (Promega, Madison, WI, USA) and bioluminescence quantified using CLZ substrate as described earlier. As shown in Figure 3b , gLuc/AAV2 capsids display a rapid exponential decline in signal, reaching near-background levels within 1 h. This rapid Figure 1 Schematic featuring transfection protocol for the production of bioluminescent Adeno-associated viral (AAV) capsids. Plasmids pVp2gLuc and pXR-ACA are transfected at the indicated ratios (total 10 mg per 15 cm plate) along with helper Ad genes (pXX6-80) and packaging construct (pTR-GFP) in HEK293 cells, as described previously. 13 Bioluminescent virion shells are generated when the Vp2gLuc protein is incorporated into AAV capsids containing Vp1 and Vp3 proteins at endogenous levels. GFP, green fluorescent protein. Bioluminescent AAV virion shells A Asokan et al decline can potentially be explained by competitive inhibition of gLuc by coelenteramide, the oxidized form of CLZ, 10 or inactivation of the enzymatic activity of gLuc by proteolysis within endosomes. Further, it is likely that irreversible conformational changes in AAV capsid proteins during the course of entry might attribute to inactivation of luciferase activity. Similar decline in bioluminescent signal has been observed during cellular uptake of retroviral particles containing firefly luciferase fused to the C-terminal of the envelope protein. 15 Taken together, the aforementioned results corroborate the use of bioluminescent AAV capsids as sensitive reporters of the kinetics of cell-surface-binding and uptake of AAV vectors.
Having established the utility of gLuc/AAV capsids in vitro, we focused our attention on live animal-imaging studies. Different gLuc/AAV serotypes were administered through intravenous (tail vein) and intramuscular (gastrocnemius) routes in mice. In particular, we chose AAV1, which is known to transduce skeletal muscle with high efficiency; 16 AAV2, being the most well-characterized AAV serotype with modest tropism for liver and muscle; 17 and AAV8, which has been shown to transduce skeletal muscle as well liver with high efficiency. 18 It is noteworthy that the gLuc-Vp2 fusion construct based on the AAV2 cap was used for these studies resulting in mosaic serotype capsids, as described earlier by Rabinowitz et al. 19 The latter report suggests that low levels of AAV2 capsid proteins, when mixed with AAV1 capsid proteins during production, do not affect the transduction profile of AAV1 in vitro. In agreement with the aforementioned findings, we have observed that the transduction profile of gLuc/AAV1 and gLuc/AAV8 capsids containing low levels of gLuc-Vp2 (derived from AAV2) remains unaltered in comparison with parental serotypes in vitro and in vivo (data not shown).
For monitoring the dynamics of AAV vectors following intramuscular injection, CLZ (5 mg kg

À1
) dissolved in methanol/PBS was first injected into the tail vein of female Balb/C mice (4-to 6-weeks old) followed immediately by injection of gLuc/AAV capsids (dose 5 Â 10 10 particles) of serotypes 1, 2 or 8 into the skeletal muscle in the left hind limb. Images were obtained at 5 min, 10 min, 30 min, 1 h and 2 h post-administration using the Xenogen IVIS 100 imaging system. As seen in (Figure 4c ), supporting previous studies that AAV8 can traverse through the blood vessel wall and distribute to peripheral tissues. 18 As shown in Figure 4d , the decrease in bioluminescent signal over time at the site of intramuscular injection corroborates results seen with in vitro studies in general. In particular, light output from gLuc/AAV2 vectors in skeletal muscle appears to decrease to background levels at a slower rate (42 h) in comparison with gLuc/AAV1 or gLuc/AAV8 vectors (30 min). Such differential kinetics might be explained by (a) a potentially faster rate of skeletal muscle cell uptake by AAV1/8 in comparison with AAV2 and/or (b) differential rate of dissemination of AAV capsids from the site of administration. The latter explanation is particularly likely given the potential for AAV2 to adhere to heparan sulfate proteoglycans, which are abundantly expressed on the surface of fast-and slow-twitch muscle fibers. 20 Such avid binding could, in turn, attenuate the dissemination of AAV2 capsids from the site of injection. Similar observations have been made with regard to dissemination of different AAV serotypes in the brain. 21, 22 The tracking of intravenously administered gLuc/ AAV capsids was precluded by the lack of sensitivity possibly arising from low concentrations of bioluminescent AAV virions in various tissues and the resulting low signal-to-background ratios (data not shown). It is likely that such studies might be possible with larger doses of viral capsids (10   12   -10 13 per mouse), currently only attainable through large-scale production.
In summary, Gaussia luciferase-labeled AAV capsids were successfully demonstrated as useful reagents for quantifying cell-surface-binding and uptake in vitro. More importantly, gLuc/AAV virion shells were detectable using live animal bioluminescence imaging in skeletal muscle. Using these reagents, we were able to demonstrate that AAV2 capsids might disseminate from the site of injection at a slower rate in comparison with AAV1/8. Alternatively, it is likely that the cellular uptake of AAV1/8 occurs at a rate faster than that of AAV2 capsids in skeletal muscle cells. Similar observations have been made with regard to the uptake and transcytosis of different AAV serotypes in epithelial cells. 23 Studies focused on delineating the underlying mechanism(s) are currently in progress. The studies described here also highlight the potential advantages of live animal tracking of viral vectors in comparison with methods that would require large numbers of animals and quantitative PCR for obtaining pharmacokinetic/ biodistribution data. It is noteworthy to mention that dual luciferase-based imaging studies can be carried out using gLuc/AAV capsids packaging a firefly luciferase cassette due to different substrate specificities of the two luciferase proteins. The relatively smaller molecular weight and higher sensitivity of Gaussia luciferase (19 kDa) in comparison with firefly luciferase (61 kDa) offers a significant advantage for incorporation into capsid proteins of enveloped or nonenveloped viruses in general. 15, 24 Bioluminescent virion shells could serve as useful tools for understanding the biology of AAV vectors in peripheral organs, especially the eye and the brain.
